financetom
Business
financetom
/
Business
/
Nobody at Tata Group anticipated the removal of Cyrus Mistry, says Mukund Rajan
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Nobody at Tata Group anticipated the removal of Cyrus Mistry, says Mukund Rajan
Apr 16, 2019 11:22 AM

Mukund Rajan, a former member of Group Executive Council at Tata Sons, in an interview with CNBC-TV18, said that nobody in the company had anticipated the removal of Cyrus Mistry.

"We had a sense that there was perhaps some tension in the air but I do not think any of us anticipated removal was on the cards. Particularly when you are discussing a position of a chairman of a board, it was not something we even deemed as within the realms of possibility. Also, some of us and I have to confess I was not one of that group, were aware that Cyrus Mistry was on a 5-year contract and at this point of time in October 2016 was 6 months away from the end of his contract. So, later when I spoke to some of my colleagues in the erstwhile Group Executive Council (GEC), some of them felt that at worst that contract might not have been renewed but a sudden termination was something that none of us saw that coming," he said.

"Both Ratan Tata and Cyrus Mistry, to my mind, were perfect gentlemen in the way they conducted themselves, the way they dealt with stakeholders, the way they treated their office staff, fellow colleagues, there is so much to learn from both of them, they are extremely grounded people. I thoroughly enjoyed my 4 years with Cyrus Mistry. There was never a sense that we were not part of a team or that we weren't in this together, that we had common challenges we were trying to address, very hard working guy, extremely bright, very sharp on the uptake. It was tragic that he and Ratan Tata who are very similar in many respects had this falling out. I have still not till this day fully understood what was the reason for that," he added.

Rajan, who is the brother of former Reserve Bank of India governor Raghuram Rajan, spoke at length about his new book 'The Brand Custodian: My Years with the Tatas'.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
ExxonMobil's Q2 Earnings: Permian Dominance Drives Production Growth, Plans $19B Buyback In FY24
ExxonMobil's Q2 Earnings: Permian Dominance Drives Production Growth, Plans $19B Buyback In FY24
Aug 2, 2024
Exxon Mobil Corporation ( XOM ) shares are trading lower after the company reported second-quarter FY24 results.  Total revenues and other income stood at $93.060 billion, beating the consensus of $90.987 billion. Net production stood at 4,358 thousand oil-equivalent barrels per day, an increase of 15% from the previous quarter, driven by increased volumes from Pioneer, Guyana, and the heritage Permian assets. Adjusted net...
Amazon says consumers cautious, forecasts revenue below Wall Street targets
Amazon says consumers cautious, forecasts revenue below Wall Street targets
Aug 2, 2024
(Corrects to paragraph 11 to say Amazon Web Services is Amazon's cloud business, not Microsoft's) By Greg Bensinger and Deborah Mary Sophia (Reuters) -Amazon.com reported slowing online sales growth in the second quarter and said cautious consumers were seeking out cheaper options for purchases, sending shares down nearly 8%. The after-hours stock drop came despite second-quarter profit and cloud computing...
TELUS International Q2 Adjusted Earnings Flat, Revenue Down; 2024 Guidance Cut
TELUS International Q2 Adjusted Earnings Flat, Revenue Down; 2024 Guidance Cut
Aug 2, 2024
09:23 AM EDT, 08/02/2024 (MT Newswires) -- TELUS International (TIXT) reported Q2 adjusted earnings Friday of $0.16 per diluted share, unchanged from a year earlier. Analysts polled by Capital IQ expected $0.26. Revenue for the quarter ended June 30 was $652 million, down from $667 million a year earlier. Analysts surveyed by Capital expected $682.4 million. The company said it...
US FDA approves Adaptimmune's gene therapy for rare type of cancer
US FDA approves Adaptimmune's gene therapy for rare type of cancer
Aug 2, 2024
Aug 2 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Adaptimmune's first-of-its-kind gene therapy to treat adult patients with a rare type of cancer that affects soft tissues who have received prior chemotherapy. Shares of the company rose about 5% in premarket trading. The therapy, branded as Tecelra, was approved to treat synovial sarcoma,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved